Tag Archives: British Society for Heart Failure (BSH)

Clinical trials update Heart failure (HF) management in the 21st century was discussed by Professor John McMurray (University of Glasgow). We are fortunate to have evidence-based medications for HF with reduced ejection fraction (HFrEF): angiotensin-converting enzyme (ACE) inhibitors, beta blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs); and now the rise of sodium glucose co-transporter 2 (SGLT2) inhibitors. Key messages from two studies with SGLT2 inhibitors – dapagliflozin in DAPA-HF1 and empagliflozin in EMPEROR-Reduced2 are: SGLT2 inhibitors reduce the risk of HF hospitalisati

Advanced heart failure From a trainee’s perspective, recognising when a heart failure (HF) patient is entering into the advanced stages is critical and sets off “transplant alarm bells”. Dr Sai Bhagra (Royal Papworth Hospital, Cambridge) delivered a great talk on this spectrum of the disease, essentially defining this as a failure of optimal therapy, requiring escalating diuretics with the development of end-organ dysfunction. The 2018 European Society of Cardiology definition of advanced HF encompasses: severe symptom limitation severe cardiac impairment pulmonary/systemic congestion requiring intravenous diuretics or malignant arrhy

No content available